Search

Your search keyword '"Bottino, Rita"' showing total 648 results
Start Over Author "Bottino, Rita"
648 results on '"Bottino, Rita"'

151. Erratum: Corrigendum: Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes

Author

Babon, Jenny Aurielle B, primary, DeNicola, Megan E, additional, Blodgett, David M, additional, Crèvecoeur, Inne, additional, Buttrick, Thomas S, additional, Maehr, René, additional, Bottino, Rita, additional, Naji, Ali, additional, Kaddis, John, additional, Elyaman, Wassim, additional, James, Eddie A, additional, Haliyur, Rachana, additional, Brissova, Marcela, additional, Overbergh, Lut, additional, Mathieu, Chantal, additional, Delong, Thomas, additional, Haskins, Kathryn, additional, Pugliese, Alberto, additional, Campbell-Thompson, Martha, additional, Mathews, Clayton, additional, Atkinson, Mark A, additional, Powers, Alvin C, additional, Harlan, David M, additional, and Kent, Sally C, additional

Published
2017
Full Text
View/download PDF

155. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 4 : pre-clinical efficacy and complication data required to justify a clinical trial

Author

Cooper, David K. C., Bottino, Rita, Gianello, Pierre, Graham, Melanie, Hawthorne, Wayne J., Kirk, Allan D., Korsgren, Olle, Park, Chung-Gyu, Weber, Collin, Cooper, David K. C., Bottino, Rita, Gianello, Pierre, Graham, Melanie, Hawthorne, Wayne J., Kirk, Allan D., Korsgren, Olle, Park, Chung-Gyu, and Weber, Collin

Abstract

In 2009, the International Xenotransplantation Association (IXA) published a consensus document that provided guidelines and recommendations (not regulations) for those contemplating clinical trials of porcine islet transplantation. These guidelines included the IXA's opinion on what constituted rigorous pre-clinical studies using the most relevant animal models and were based on non-human primate testing. We now report our discussion following a careful review of the 2009 guidelines as they relate to pre-clinical testing. In summary, we do not believe there is a need to greatly modify the conclusions and recommendations of the original consensus document. Pre-clinical studies should be sufficiently rigorous to provide optimism that a clinical trial is likely to be safe and has a realistic chance of success, but need not be so demanding that success might only be achieved by very prolonged experimentation, as this would not be in the interests of patients whose quality of life might benefit immensely from a successful islet xenotransplant. We believe these guidelines will be of benefit to both investigators planning a clinical trial and to institutions and regulatory authorities considering a proposal for a clinical trial. In addition, we suggest consideration should be given to establishing an IXA Clinical Trial Advisory Committee that would be available to advise (but not regulate) researchers considering initiating a clinical trial of xenotransplantation.

Published
2016
Full Text
View/download PDF

156. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, Cooper, David K C, Bottino, Rita, Gianello, Pierre, Graham, Melanie, Hawthorne, Wayne J, Kirk, Allan D, Korsgren, Olle, Park, Chung-Gyu, Weber, Collin, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, Cooper, David K C, Bottino, Rita, Gianello, Pierre, Graham, Melanie, Hawthorne, Wayne J, Kirk, Allan D, Korsgren, Olle, Park, Chung-Gyu, and Weber, Collin

Abstract

In 2009, the International Xenotransplantation Association (IXA) published a consensus document that provided guidelines and "recommendations" (not regulations) for those contemplating clinical trials of porcine islet transplantation. These guidelines included the IXA's opinion on what constituted "rigorous pre-clinical studies using the most relevant animal models" and were based on "non-human primate testing." We now report our discussion following a careful review of the 2009 guidelines as they relate to pre-clinical testing. In summary, we do not believe there is a need to greatly modify the conclusions and recommendations of the original consensus document. Pre-clinical studies should be sufficiently rigorous to provide optimism that a clinical trial is likely to be safe and has a realistic chance of success, but need not be so demanding that success might only be achieved by very prolonged experimentation, as this would not be in the interests of patients whose quality of life might benefit immensely from a successful islet xenotransplant. We believe these guidelines will be of benefit to both investigators planning a clinical trial and to institutions and regulatory authorities considering a proposal for a clinical trial. In addition, we suggest consideration should be given to establishing an IXA Clinical Trial Advisory Committee that would be available to advise (but not regulate) researchers considering initiating a clinical trial of xenotransplantation.

Published
2016

157. Potential for clinical pancreatic islet xenotransplantation

Author

Bottino, Rita, Nagaraju,Santosh, Satyananda,Vikas, Hara,Hidetaka, Wijkstrom,Martin, Massimo,Trucco, and Cooper,David K

Subjects
endocrine system, Transplant Research and Risk Management
Abstract

Rita Bottino,1 Santosh Nagaraju,2 Vikas Satyananda,2 Hidetaka Hara,2 Martin Wijkstrom,2 Massimo Trucco,1 David KC Cooper2 1Institute of Cellular Therapeutics, Allegheny Health Network, 2Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA Abstract: Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated successfully by islet allotransplantation, the results of which are steadily improving. However, the number of islets that can be obtained from deceased human donors will never be sufficient to cure more than a very small percentage of patients who might benefit from transplantation. Although there are some differences in glucose metabolism between pigs and humans, the use of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly control glucose levels. Transplantation of islets into the portal vein results in islets residing in the liver; however, an early inflammatory response and rejection remain problematic, even when the recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsulation techniques provide islets with a physical barrier that prevents antibodies binding to the islet graft while still allowing insulin to be released into the recipient's circulation; in theory, patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic structure of pigs closer to that of humans, and providing protection from the human immune response. Islet transplantation from genetically engineered pigs has been followed by insulin independence in a small number of nonhuman primates for greater than 1 year. Neonatal islets have some advantages over adult islets in that they are easier to isolate and culture, and have the ability to proliferate during the first few months after transplantation. In 2009, the International Xenotransplantation Association set up a group to encourage and advise on clinical trials of pig islet xenotransplantation; this group's guidelines are discussed. Clinical trials of encapsulated pig islets are already under way. Keywords: diabetes, islets, pancreatic, pig, xenotransplantation

Published
2014

162. Endoscopic biopsy of islet transplants in the gastric submucosal space provides evidence of islet graft rejection in diabetic pigs

Author

Tanaka, Takayuki, primary, Fujita, Minoru, additional, Bottino, Rita, additional, Piganelli, Jon D., additional, McGrath, Kevin, additional, Li, Jiang, additional, Lee, Whayoung, additional, Iwase, Hayato, additional, Wijkstrom, Martin, additional, Bertera, Suzanne, additional, Long, Cassandra, additional, Landsittel, Douglas, additional, Haruma, Ken, additional, Cooper, David K.C., additional, and Hara, Hidetaka, additional

Published
2016
Full Text
View/download PDF

163. Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Author

Marre, Meghan L., McGinty, John W., I-Ting Chow, DeNicola, Megan E., Beck, Noah W., Kent, Sally C., Powers, Alvin C., Bottino, Rita, Harlan, David M., Greenbaum, Carla J., Kwok, William W., Piganelli, Jon D., James, Eddie A., and Chow, I-Ting

Subjects
TYPE 1 diabetes, T cells, AUTOIMMUNITY, LYMPHOCYTES, IMMUNITY
Abstract

In spite of tolerance mechanisms, some individuals develop T-cell-mediated autoimmunity. Posttranslational modifications that increase the affinity of epitope presentation and/or recognition represent one means through which self-tolerance mechanisms can be circumvented. We investigated T-cell recognition of peptides that correspond to modified β-cell antigens in subjects with type 1 diabetes. Modified peptides elicited enhanced proliferation by autoreactive T-cell clones. Endoplasmic reticulum (ER) stress in insulinoma cells increased cytosolic calcium and the activity of tissue transglutaminase 2 (tTG2). Furthermore, stressed human islets and insulinomas elicited effector responses from T cells specific for modified peptides, suggesting that ER stress-derived tTG2 activity generated deamidated neoepitopes that autoreactive T cells recognized. Patients with type 1 diabetes had large numbers of T cells specific for these epitopes in their peripheral blood. T cells with these specificities were also isolated from the pancreatic draining lymph nodes of cadaveric donors with established diabetes. Together, these results suggest that self-antigens are enzymatically modified in β-cells during ER stress, giving rise to modified epitopes that could serve to initiate autoimmunity or to further broaden the antigenic repertoire, activating potentially pathogenic CD4+ T cells that may not be effectively eliminated by negative selection. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

167. Author Response to Letter by Delibasi T., et al

Author

Johnston, Philip C., primary, Bottino, Rita, additional, Trucco, Massimo, additional, Lin, Yu Kuei, additional, Walsh, R. Matthew, additional, Stevens, Tyler K., additional, Bena, James, additional, and Hatipoglu, Betul A., additional

Published
2015
Full Text
View/download PDF

168. Bioengineering Thymus Organoids to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts

Author

Fan, Yong, primary, Tajima, Asako, additional, Goh, Saik Kia, additional, Geng, Xuehui, additional, Gualtierotti, Giulio, additional, Grupillo, Maria, additional, Coppola, Antonina, additional, Bertera, Suzanne, additional, Rudert, William A, additional, Banerjee, Ipsita, additional, Bottino, Rita, additional, and Trucco, Massimo, additional

Published
2015
Full Text
View/download PDF

169. Factors associated with islet yield and insulin independence after total pancreatectomy and islet cell autotransplantation in patients with chronic pancreatitis utilising off-site islet isolation: Cleveland Clinic experience

Author

Johnston, Philip C, primary, Lin, Yu, additional, Walsh, Matthew, additional, Stevens, Tyler, additional, Bottino, Rita, additional, Trucco, Massimo, additional, Bena, James, additional, and Hatipoglu, Betul, additional

Published
2015
Full Text
View/download PDF

172. Potential for clinical pancreatic islet xenotransplantation

Author

Bottino,Rita, Nagaraju,Santosh, Satyananda,Vikas, Hara,Hidetaka, Wijkstrom,Martin, Trucco,Massimo, Cooper,David KC, Bottino,Rita, Nagaraju,Santosh, Satyananda,Vikas, Hara,Hidetaka, Wijkstrom,Martin, Trucco,Massimo, and Cooper,David KC

Abstract

Rita Bottino,1 Santosh Nagaraju,2 Vikas Satyananda,2 Hidetaka Hara,2 Martin Wijkstrom,2 Massimo Trucco,1 David KC Cooper2 1Institute of Cellular Therapeutics, Allegheny Health Network, 2Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA Abstract: Diabetes mellitus is increasing worldwide. Type 1 diabetes can be treated successfully by islet allotransplantation, the results of which are steadily improving. However, the number of islets that can be obtained from deceased human donors will never be sufficient to cure more than a very small percentage of patients who might benefit from transplantation. Although there are some differences in glucose metabolism between pigs and humans, the use of pigs could provide an unlimited supply of islets, and the insulin produced would undoubtedly control glucose levels. Transplantation of islets into the portal vein results in islets residing in the liver; however, an early inflammatory response and rejection remain problematic, even when the recipient is receiving immunosuppressive therapy. In the long term, immunosuppressive drugs may exhibit toxicities to patients and specifically harm the islet cells. In contrast, encapsulation techniques provide islets with a physical barrier that prevents antibodies binding to the islet graft while still allowing insulin to be released into the recipient's circulation; in theory, patients receiving encapsulated grafts might not require exogenous immunosuppressive therapy. Nonhuman primates with encapsulated pig islet transplants have remained insulin-independent for several weeks, but long-term efficacy remains uncertain. Furthermore, techniques are now available to knock out genes from the pig and/or insert human genes, thus rendering the antigenic structure of pigs closer to that of humans, and providing protection from the human immune response. Islet transplantation from genetically engineered pigs has been followed by

Published
2014

173. Glucose metabolism in pigs expressing human genes under an insulin promoter

Author

Wijkstrom, Martin, primary, Bottino, Rita, additional, Iwase, Hayoto, additional, Hara, Hidetaka, additional, Ekser, Burcin, additional, van der Windt, Dirk, additional, Long, Cassandra, additional, Toledo, Frederico G. S., additional, Phelps, Carol J., additional, Trucco, Massimo, additional, Cooper, David K. C., additional, and Ayares, David, additional

Published
2014
Full Text
View/download PDF

174. Safe use of anti- CD154 monoclonal antibody in pig islet xenotransplantation in monkeys.

Author

Bottino, Rita, Knoll, Michael F., Graeme‐Wilson, Joshua, Klein, Edwin C., Ayares, David, Trucco, Massimo, and Cooper, David K. C.

Subjects
*MONOCLONAL antibodies, *XENOTRANSPLANTATION, *MONKEY diseases, *PEOPLE with diabetes, *TRANSGENIC organisms
Abstract

Anti- CD154mAb is a powerful co-stimulation blockade agent that is efficacious in preventing rejection, even in xenogeneic settings. It has been used in the majority of successful long-term pig-to-non-human primate islet transplantation models. However, its clinical use was halted as a result of thromboembolic complications that were also observed in preclinical and clinical organ transplantation models. An anti- CD154mAb was administered to 14 streptozotocin-induced diabetic cynomolgus monkey recipients of porcine islets, some of which received the agent for many months. Monkeys were monitored for complications, and blood monitoring was carried out frequently. After euthanasia, multiple biopsies of all organs were examined for histological features of thromboembolism. Anti- CD154mAb prevented rejection of genetically engineered pig islets in all monkeys. No significant complications were attributable specifically to anti- CD154mAb. There was no evidence of thromboembolism in multiple histological sections from all major organs, including the brain. Our data suggest that in diabetic monkeys with pig islet grafts, anti- CD154mAb would appear to be an effective and safe therapy, and is not associated with thromboembolic complications. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

178. The Histopathology of PRSS1 Hereditary Pancreatitis

Author

Singhi, Aatur D., primary, Pai, Reetesh K., additional, Kant, Jeffrey A., additional, Bartholow, Tanner L., additional, Zeh, Herbert J., additional, Lee, Kenneth K., additional, Wijkstrom, Martin, additional, Yadav, Dhiraj, additional, Bottino, Rita, additional, Brand, Randall E., additional, Chennat, Jennifer S., additional, Lowe, Mark E., additional, Papachristou, Georgios I., additional, Slivka, Adam, additional, Whitcomb, David C., additional, and Humar, Abhinav, additional

Published
2014
Full Text
View/download PDF

180. Technique of Endoscopic Biopsy of Islet Allografts Transplanted into the Gastric Submucosal Space in Pigs

Author

Fujita, Minoru, primary, McGrath, Kevin M., additional, Bottino, Rita, additional, Dons, Eefje M., additional, Long, Cassandra, additional, Kumar, Goutham, additional, Ekser, Burcin, additional, Echeverri, Gabriel J., additional, Hata,‡‡, Jiro, additional, Haruma, Ken, additional, Cooper, David K. C., additional, and Hara, Hidetaka, additional

Published
2013
Full Text
View/download PDF

182. Cytokine and chemokine production by human pancreatic islets upon enterovirus infection

Author

LS Virologie, Schulte, Barbara M, Lanke, Kjerstin H W, Piganelli, Jon D, Kers-Rebel, Esther D, Bottino, Rita, Trucco, Massimo, Huijbens, Richard J F, Radstake, Timothy R D J, Engelse, Marten A, de Koning, Eelco J P, Galama, Jochem M, Adema, Gosse J, van Kuppeveld, Frank J M, LS Virologie, Schulte, Barbara M, Lanke, Kjerstin H W, Piganelli, Jon D, Kers-Rebel, Esther D, Bottino, Rita, Trucco, Massimo, Huijbens, Richard J F, Radstake, Timothy R D J, Engelse, Marten A, de Koning, Eelco J P, Galama, Jochem M, Adema, Gosse J, and van Kuppeveld, Frank J M

Published
2012

186. Multi‐transgenic pigs for xenoislet transplantation

Author

Ayares, David, primary, Phelps, Carol, additional, Vaught, Todd, additional, Ball, Suyapa, additional, Monahan, Jeff, additional, Walters, Anneke, additional, Giraldo, Angelica, additional, Bertera, Suzanne, additional, van der Windt, Dirk, additional, Wijkstrom, Martin, additional, Cooper, David K. C., additional, Bottino, Rita, additional, and Trucco, Massimo, additional

Published
2013
Full Text
View/download PDF

188. Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human β Cell Function.

Author

Arda, H. Efsun, Li, Lingyu, Tsai, Jennifer, Torre, Eduardo A., Rosli, Yenny, Peiris, Heshan, Spitale, Robert C., Dai, Chunhua, Gu, Xueying, Qu, Kun, Wang, Pei, Wang, Jing, Grompe, Markus, Scharfmann, Raphael, Snyder, Michael S., Bottino, Rita, Powers, Alvin C., Chang, Howard Y., and Kim, Seung K.

Abstract

Summary Intensive efforts are focused on identifying regulators of human pancreatic islet cell growth and maturation to accelerate development of therapies for diabetes. After birth, islet cell growth and function are dynamically regulated; however, establishing these age-dependent changes in humans has been challenging. Here, we describe a multimodal strategy for isolating pancreatic endocrine and exocrine cells from children and adults to identify age-dependent gene expression and chromatin changes on a genomic scale. These profiles revealed distinct proliferative and functional states of islet α cells or β cells and histone modifications underlying age-dependent gene expression changes. Expression of SIX2 and SIX3 , transcription factors without prior known functions in the pancreas and linked to fasting hyperglycemia risk, increased with age specifically in human islet β cells. SIX2 and SIX3 were sufficient to enhance insulin content or secretion in immature β cells. Our work provides a unique resource to study human-specific regulators of islet cell maturation and function. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

189. Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Author

Lee, Whayoung, Hara, Hidetaka, Ezzelarab, Mohamed B., Iwase, Hayato, Bottino, Rita, Long, Cassandra, Ramsoondar, Jagdeece, Ayares, David, and Cooper, David K.C.

Subjects
IN vitro studies, CELL transplantation, ERYTHROCYTES, BLOOD platelet aggregation, LABORATORY swine
Abstract

Absract Background The impact that the absence of expression of NeuGc in pigs might have on pig organ or cell transplantation in humans has been studied in vitro, but only using red blood cells (p RBCs) and peripheral blood mononuclear cells (p PBMCs) as the target cells for immune assays. We have extended this work in various in vitro models and now report our initial results. Methods The models we have used involve GTKO/hCD46 and GTKO/hCD46/NeuGcKO pig aortas and corneas, and p RBCs, p PBMCs, aortic endothelial cells (p AECs), corneal endothelial cells (p CECs), and isolated pancreatic islets. We have investigated the effect of the absence of NeuGc expression on (i) human IgM and IgG binding, (ii) the T-cell proliferative response, (iii) human platelet aggregation, and (iv) in an in vitro assay of the instant blood-mediated inflammatory reaction ( IBMIR) following exposure of pig islets to human blood/serum. Results The lack of expression of NeuGc on some pig tissues (aortas, corneas) and cells ( RBCs, PBMCs, AECs) significantly reduces the extent of human antibody binding. In contrast, the absence of NeuGc expression on some pig tissues ( CECs, isolated islet cells) does not reduce human antibody binding, possibly due to their relatively low NeuGc expression level. The strength of the human T-cell proliferative response may also be marginally reduced, but is already weak to GTKO/hCD46 p AECs and islet cells. We also demonstrate that the absence of NeuGc expression on GTKO/hCD46 pAECs does not reduce human platelet aggregation, and nor does it significantly modify the IBMIR to pig islets. Conclusion The absence of NeuGc on some solid organs from GTKO/hCD46/NeuGcKO pigs should reduce the human antibody response after clinical transplantation when compared to GTKO/hCD46 pig organs. However, the clinical benefit of using certain tissue (e.g., cornea, islets) from GTKO/hCD46/NeuGcKO pigs is questionable. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

190. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial

Author

Cooper, David K.C., Bottino, Rita, Gianello, Pierre, Graham, Melanie, Hawthorne, Wayne J., Kirk, Allan D., Korsgren, Olle, Park, Chung‐Gyu, and Weber, Collin

Subjects
*XENOGRAFTS, *CLINICAL trials, *XENOTRANSPLANTATION, *ANIMAL health, *SWINE, *SOCIETIES
Abstract

In 2009, the International Xenotransplantation Association ( IXA) published a consensus document that provided guidelines and 'recommendations' ( not regulations) for those contemplating clinical trials of porcine islet transplantation. These guidelines included the IXA's opinion on what constituted 'rigorous pre-clinical studies using the most relevant animal models' and were based on 'non-human primate testing.' We now report our discussion following a careful review of the 2009 guidelines as they relate to pre-clinical testing. In summary, we do not believe there is a need to greatly modify the conclusions and recommendations of the original consensus document. Pre-clinical studies should be sufficiently rigorous to provide optimism that a clinical trial is likely to be safe and has a realistic chance of success, but need not be so demanding that success might only be achieved by very prolonged experimentation, as this would not be in the interests of patients whose quality of life might benefit immensely from a successful islet xenotransplant. We believe these guidelines will be of benefit to both investigators planning a clinical trial and to institutions and regulatory authorities considering a proposal for a clinical trial. In addition, we suggest consideration should be given to establishing an IXA Clinical Trial Advisory Committee that would be available to advise (but not regulate) researchers considering initiating a clinical trial of xenotransplantation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

191. Current status of islet xenotransplantation.

Author

Park, Chung-Gyu, Bottino, Rita, and Hawthorne, Wayne J.

Abstract

Cell therapy for Type 1 diabetes (T1D) utilizing islet cell transplantation can successfully restore endogenous insulin production in affected patients. Islet cell engraftment and survival are conditional on the use of efficacious anti-rejection therapies and on the availability of healthy donor cells. The scarcity of healthy human donor pancreata is a limiting factor in providing sufficient tissue to meet the demand for islet transplantation worldwide. A potential alternative to the use of cadaveric human donor pancreases is the use of animal sourced islets. Pancreatic islets obtained from pigs have emerged as an alternative to human tissues due to their great availability, physiological similarities to human islets, including the time-tested use of porcine insulin in diabetic patients and the ability to genetically modify the donor source. The evolution of refined, efficacious immunosuppressive therapies with reduced toxicity, improvements in donor management and genetic manipulation of the donor have all contributed to facilitate long-term function in pre-clinical models of pig islet grafts in non-human primates. As clinical consideration for this option is growing, and trials involving the use of porcine islets have begun, more compelling experimental data suggest that the use of pig islets may soon become a viable, safe, effective and readily available treatment for insulin deficiency in T1D patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

193. Clinical Islet Xenotransplantation

Author

van der Windt, Dirk J., primary, Bottino, Rita, additional, Kumar, Goutham, additional, Wijkstrom, Martin, additional, Hara, Hidetaka, additional, Ezzelarab, Mohamed, additional, Ekser, Burcin, additional, Phelps, Carol, additional, Murase, Noriko, additional, Casu, Anna, additional, Ayares, David, additional, Lakkis, Fadi G., additional, Trucco, Massimo, additional, and Cooper, David K.C., additional

Published
2012
Full Text
View/download PDF

195. Cytokine and Chemokine Production by Human Pancreatic Islets Upon Enterovirus Infection

Author

Schulte, Barbara M., primary, Lanke, Kjerstin H.W., additional, Piganelli, Jon D., additional, Kers-Rebel, Esther D., additional, Bottino, Rita, additional, Trucco, Massimo, additional, Huijbens, Richard J.F., additional, Radstake, Timothy R.D.J., additional, Engelse, Marten A., additional, de Koning, Eelco J.P., additional, Galama, Jochem M., additional, Adema, Gosse J., additional, and van Kuppeveld, Frank J.M., additional

Published
2012
Full Text
View/download PDF

199. Isolation of Human Islets for Autologous Islet Transplantation in Children and Adolescents with Chronic Pancreatitis

Author

Bottino, Rita, primary, Bertera, Suzanne, additional, Grupillo, Maria, additional, Melvin, Patricia R., additional, Humar, Abhinav, additional, Mazariegos, George, additional, Moser, A. James, additional, Walsh, R. Matthew, additional, Fung, John, additional, Gelrud, Andres, additional, Slivka, Adam, additional, Soltys, Kyle, additional, Wijkstrom, Martin, additional, and Trucco, Massimo, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results